Corcept extends exclusive specialty pharmacy agreement for Korlym with Optime to March 2024

CORCEPT THERAPEUTICS INC

Amendment extends Optime's exclusive dispensing services for Korlym to March 31, 2024.
No financial terms disclosed; original agreement from August 2017.
Optime remains sole specialty pharmacy for Korlym in the United States.

item 1.01

CORCEPT THERAPEUTICS INC filing history →

Source: SEC EDGAR

accession 0001193125-22-249225

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.